4 results
In the current study we investigate the safety of the HBAI20 vaccine. Furthermore, the efficacy of the HBAI20 vaccine in non-responders is investigated.
To characterize safety, tolerability, pharmacodynamic effects, and pharmacokinetics of the oral sGC stimulator BAY 1021189 in addition to standard therapy for heart failure with reduced EF (HFrEF) over 12 weeks in patients with worsening chronic…
Primary:to assess the glycemic effects of a single dose of OXM on the ambient glucose levels during a GGI assessmentto assess the insulinotropic effects of a single dose of OXM measured as a change in "*" during a GGI assessmentSecondary:…
In the Phase 2 clinical study, the efficacy of the vaccine in non-responders and the safety of the vaccine will be studied.